Elan shares plummet after withdrawal of new MS drug

Ireland's Largest drug company, Elan, lost more than two-thirds of its stock market value yesterday after it was forced to pull its multiple sclerosis drug from the US market after just three months.

The company revealed that two people taking Tysabri may have contracted a serious disease of the nervous system. One of the patients has died and the company said it was stopping marketing the drug while it examines whether it can be linked to the incident.

Elan is the fourth largest company on the Irish stock market, which posted its biggest one-day drop in seven years as a result of the news. Elan's shares, which are also traded in London, fell from €20.44 (£14.09) to €6.35.

Biogen Idec, the giant US biotech company which helped to develop and now markets Tysabri (previously known as Antegren), lost more than 40 per cent of its value. The pair said they believed the drug could return to market later this year after a safety investigation. Analysts were doubtful, and most agreed there was now little chance Tysabri will meet hopes of up to $3bn (£1.6bn) in annual sales. It could return with stronger safety warnings on the label.

Daniel Mahony, of Morgan Stanley, said: "Tysabri had been approved in the US on the back of some impressive efficacy data and we had expected the agent to take significant market share. However, these new safety issues raise significant questions on its potential."

About 2,600 people are in clinical trials for the drug, taken via injection, and a further 3,000 are now taking it on a commercial basis after its approval by the US Food & Drug Administration in November. It has not yet been approved for launch in Europe.

Multiple sclerosis targets the central nervous system and can cause blurred vision, weakness, poor muscle co-ordination and loss of memory. Tysabri's US approval came earlier than usual because the drug appeared so effective in early trials. Its withdrawal yesterday turns it from one of the biotech industry's most exciting prospects to potentially one of its most disappointing failures.

Trials showed it can improve the effectiveness of older drugs for MS, including Biogen's Avonex. After two years of using the two drugs in combination, one patient died of a rare and often fatal nervous system disorder known as progressive multifocal leukoencephalopathy and another is suspected of contracting it.

All clinical trials of Tysabri, including some aimed at proving it can also treat rheumatoid arthritis, have been suspended.

The problems with Tysabri come amid rising concern over the risks of major drugs, and follow the withdrawal of the widely prescribed painkiller Vioxx, which has been linked to increased risks of heart attacks and became the biggest-ever drug withdrawal last September. Regulators, particularly in the US, have been accused of not paying enough attention to the potential side effects of new drugs.

Yesterday's news is also the latest extraordinary twist in the story of Elan. At the height of the biotech bubble in 2000, it was Ireland's largest company, but it was partly a financial construct, recycling the company's own money via collaborations with small, experimental drug developers, to give the illusion of higher revenues and assets.

It recently paid $100m in fines and legal settlements over allegations of misleading accounting.

Start your day with The Independent, sign up for daily news emails
News
election 2015The 10 best quotes of the campaign
News
A caravan being used as a polling station in Ford near Salisbury, during the 2010 election
election 2015The Independent's guide to get you through polling day
News
people
Voices
David Blunkett joins the Labour candidate for Redcar Anna Turley on a campaigning visit last month
voicesWhat I learnt from my years in government, by the former Home Secretary David Blunkett
ebooks
ebooksA celebration of British elections
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Ashdown Group: Editor-in-chief - Financial Services - City, London

£60000 - £70000 per annum + benefits : Ashdown Group: A highly successful, glo...

Ashdown Group: Junior Application Support Analyst - Fluent German Speaker

£25000 - £30000 per annum + benefits: Ashdown Group: A global leader operating...

Guru Careers: Management Accountant

£27 - 35k + Bonus + Benefits: Guru Careers: A Management Accountant is needed ...

Guru Careers: Project Manager / Business Analyst

£40-50k + Benefits.: Guru Careers: A Project Manager / Business Analyst is nee...

Day In a Page

General Election 2015: ‘We will not sit down with Nicola Sturgeon’, says Ed Balls

'We will not sit down with Nicola Sturgeon'

In an exclusive interview, Ed Balls says he won't negotiate his first Budget with SNP MPs - even if Labour need their votes to secure its passage
VE Day 70th anniversary: How ordinary Britons celebrated the end of war in Europe

How ordinary Britons celebrated VE Day

Our perception of VE Day usually involves crowds of giddy Britons casting off the shackles of war with gay abandon. The truth was more nuanced
They came in with William Caxton's printing press, but typefaces still matter in the digital age

Typefaces still matter in the digital age

A new typeface once took years to create, now thousands are available at the click of a drop-down menu. So why do most of us still rely on the old classics, asks Meg Carter?
Discovery of 'missing link' between the two main life-forms on Earth could explain evolution of animals, say scientists

'Missing link' between Earth's two life-forms found

New microbial species tells us something about our dark past, say scientists
The Pan Am Experience is a 'flight' back to the 1970s that never takes off - at least, not literally

Pan Am Experience: A 'flight' back to the 70s

Tim Walker checks in and checks out a four-hour journey with a difference
Humans aren't alone in indulging in politics - it's everywhere in the animal world

Humans aren't alone in indulging in politics

Voting, mutual back-scratching, coups and charismatic leaders - it's everywhere in the animal world
Crisp sales are in decline - but this tasty trivia might tempt back the turncoats

Crisp sales are in decline

As a nation we're filling up on popcorn and pitta chips and forsaking their potato-based predecessors
Ronald McDonald the muse? Why Banksy, Ron English and Keith Coventry are lovin' Maccy D's

Ronald McDonald the muse

A new wave of artists is taking inspiration from the fast food chain
13 best picnic blankets

13 best picnic blankets

Dine al fresco without the grass stains and damp bottoms with something from our pick of picnic rugs
Barcelona 3 Bayern Munich 0 player ratings: Lionel Messi scores twice - but does he score highest in our ratings?

Barcelona vs Bayern Munich player ratings

Lionel Messi scores twice - but does he score highest in our ratings?
Martin Guptill: Explosive New Zealand batsman who sets the range for Kiwis' big guns

Explosive batsman who sets the range for Kiwis' big guns

Martin Guptill has smashed early runs for Derbyshire and tells Richard Edwards to expect more from the 'freakish' Brendon McCullum and his buoyant team during their tour of England
General Election 2015: Ed Miliband's unlikely journey from hapless geek to heart-throb

Miliband's unlikely journey from hapless geek to heart-throb

He was meant to be Labour's biggest handicap - but has become almost an asset
General Election 2015: A guide to the smaller parties, from the the National Health Action Party to the Church of the Militant Elvis Party

On the margins

From Militant Elvis to Women's Equality: a guide to the underdogs standing in the election
Amr Darrag: Ex-Muslim Brotherhood minister in exile still believes Egypt's military regime can be replaced with 'moderate' Islamic rule

'This is the battle of young Egypt for the future of our country'

Ex-Muslim Brotherhood minister Amr Darrag still believes the opposition can rid Egypt of its military regime and replace it with 'moderate' Islamic rule, he tells Robert Fisk
Why patients must rely less on doctors: Improving our own health is the 'blockbuster drug of the century'

Why patients must rely less on doctors

Improving our own health is the 'blockbuster drug of the century'